Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia.
Taub
J W
JW
Matherly
L H
LH
Ravindranath
Y
Y
Kaspers
G J L
GJ
Rots
M G
MG
Zantwijk
C H
CH
D000293:Adolescent; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004273:DNA, Neoplasm / Q000378:metabolism; D004351:Drug Resistance; D005838:Genotype; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007223:Infant; D008727:Methotrexate / Q000494:pharmacology* / Q000627:therapeutic use; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*
D000964:Antimetabolites, Antineoplastic; D004273:DNA, Neoplasm; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008727:Methotrexate